ClinicalTrials.Veeva

Menu

Artificial Tears Study in Mild to Moderate Dry Eye Patients

Abbott logo

Abbott

Status and phase

Completed
Phase 2

Conditions

Dry Eye

Treatments

Drug: Systane
Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Study type

Interventional

Funder types

Industry

Identifiers

NCT00607776
PEGT-104-9582

Details and patient eligibility

About

The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.

Enrollment

110 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Mild to moderate dry eye
  • over 18

Exclusion criteria

  • No concurrent ocular disease or meds

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

110 participants in 2 patient groups

1
Active Comparator group
Description:
Systane
Treatment:
Drug: Systane
2
Experimental group
Description:
Blink tears
Treatment:
Drug: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems